

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituted Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,513
Filing Date	February 23, 2004
First Named Inventor	Gorski, et al.
Art Unit	1645
Examiner Name	Not yet assigned
Attorney Docket Number	22311/04024

Sheet 1 of 2

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
RH		US- 5,851,521	12/22/1998	Branellec, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ³
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

2/22/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,513
Filing Date	February 23, 2004
First Named Inventor	Gorski, et al.
Art Unit	1645
Examiner Name	Not yet assigned
Attorney Docket Number	22311/04024

Sheet


2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RI		"Targeted vectors for gene therapy" by Miller, et al. FASEB J. 9, 190-199 (1995).	
1		"Gene therapy - promises, problems and prospects" by Verma, et al., Nature, Vol. 389, 18 September 0997, pp. 239-242.	
		"Gene Therapy: Promises and Problems" by Pfeifer, et al., Annu. Rev. Genomics Hum. Genet. 2001, 2:177-211.	
		Chapter 5, "Gene-Based Therapy" by Eck, et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 1996, McGraw-Hill, New York, NY	
		"Transgenic and therapeutic targeting of smooth muscle cells and the challenges presented by phenotypic diversity" by Strauch, et al., Emerging Therapeutic Targets (1999) 3(2):279-306.	


Examiner
Signature

Date
Considered

2/22/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Subst. Exam PTO-1449 APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 22311/04024	Serial No.: 10/784,513
	Applicant: Gorski, et al.	
	Filing Date: February 23, 2004	Group: Not yet assigned

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
RH	AA	5,302,706	April 12, 1994	Smith			Nov. 2, 1992
	AB	5,856,121	January 5, 1999	Gorski, et al.			Feb. 24, 1994
	AC	6,280,969	August 28, 1991	Gorski, et al.			May 14, 1998
	AD						

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
	AE						
	AF						
	AG						
	AH						
	AI						

OTHER PRIOR ART

	AJ	"Molecular Cloning of a Homeobox Transcription Factor from Adult Aortic Smooth Muscle" by Patel, et al., <u>The Journal of Biological Chemistry</u> , Vol. 267, No. 36, December 25, 1992, pp. 26085-26090.
	AK	"Molecular Cloning of a Diverged Homeobox Gene that is Rapidly Down-Regulated During the G ₀ /G ₁ Transition in Vascular Smooth Muscle Cells" by Gorski, et al., <u>Molecular and Cellular Biology</u> , Vol. 13, No. 6, June 1993, pp. 3722-3733.
	AL	"Homeobox Transcription Factor Regulation in the Cardiovascular System" by Gorski, et al., <u>TCM</u> , Vol. 3, No. 5, 1993, pp. 184-190.
	AM	"Cloning and Sequence Analysis of Homeobox Transcription Factor cDNA's with an Inosine-Containing Probe" by Gorski, et al., <u>Short Technical Reports</u> , Vol. 15, No. 5, 1994.
	AN	"The Growth Arrest-Specific Gene, <i>gas1</i> , Is Involved in Growth Suppression" by Del Sal, et al., <u>International Centre for Genetic Engineering and Biotechnology</u> , August 21, 1992, pp. 595-607.
	AO	"Cloning of Senescent Cell-Derived Inhibitors of DNA Synthesis Using an Expression Screen" by Noda, et al., <u>Experimental Cell Research</u> , 211, 1994, pp. 90-98.
	AP	"CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G ₁ /S arrest" by Barone, et al., <u>Genes and Development</u> , 8, 1994, pp. 453-464.
	AQ	" <i>Mox-1</i> and <i>Mox-2</i> define a novel homeobox gene subfamily and are differentially expressed during early mesodermal patterning in mouse embryos" by Candia, et al., <u>Development</u> , 116, August 28, 1992, pp. 1123-1136.
	AR	"Arterial Gene Transfer Using Pure DNA Applied Directly to a Hydrogel-Coated Aniooplasty Balloon" by Riessen, et al., <u>Human Gene Therapy</u> , 4, 1993, pp. 749-758.
	AS	"Antisense <i>c-myb</i> oligonucleotides inhibit intimal arterial smooth muscle cell accumulation <i>in vivo</i> " by Simons, et al., <u>Nature</u> , Vol. 359, September 3, 1992, pp. 67-70.

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

2/22/07

Subst. Form PTO-1449 APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 22311/04024	Serial No.: 10/784,513
	Applicant: Gorski, et al.	
	Filing Date: February 23, 2004	Group: Not yet assigned

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA						
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
	AE						
	AF						
	AG						
	AH						
	AI						

OTHER PRIOR ART

RL	AJ	"Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall" by Nabel, et al., <u>Reports</u> , September 14, 1990, pp. 1285-1288.
	AK	"Low Level In Vivo Gene Transfer Into the Arterial Wall Through a Perforated Balloon Catheter" by Flugelman, et al., <u>Circulation</u> , Vol. 85, No. 3, March 1992, pp. 1110-1117.
	AL	"Single-step purification of polypeptides expressed in <i>Escherichia coli</i> as fusions with glutathione S-transferase" by Smith, et al., <u>Gene</u> , 67, 1988, pp. 31-40.
	AM	"Molecular Cloning and Localization of the Human <i>Gax</i> Gene to 7p21" by LePage, et al., <u>Genomics</u> , 24, 1994, pp. 535-540.
	AN	"Amino acid sequence of Mox-2 and comparison to its <i>Xenopus</i> and rat homologs" by Candia, et al., <u>Nucleic Acids Research</u> , Vol. 21, No. 21, 1993 p. 4982.
	AO	Exhibit A is the gene sequence for the rat <i>Gax</i> cDNA (2244 base pairs) submitted by Kenneth Walsh, released to the public February 28, 1993.
	AP	Exhibit B ₁ is a gene sequence for Mox-1 (2182 base pairs) (mistakenly designated "Mox-2") submitted by A.F. Candia to New GenBank and created on September 25, 1992.
	AQ	"Exhibit B ₂ is the same gene sequence as Exhibit B ₁ except the former designation "Mox-2" has been corrected to read "Mox-1".
	AR	Exhibit C is the partial gene sequence for mouse Mox-2A submitted by A.F. Candia to GenBank and created on October 5, 1992.
	AS	Exhibit D is the revision of Exhibit C to show the 1440 base pair mouse Mox-2 sequence on March 6, 1993.
	AT	Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox" by Ngo, et al., <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , K. Merz, Jr. and S. Le Grand, Editors, Birkhäuser Boston 1994.
-Examiner:		Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

